In EMS, why is aspirin described as an antiplatelet agent?

In EMS, why is aspirin described as an antiplatelet agent?

• A. It inhibits platelet aggregation, helping prevent further clot formation during a suspected myocardial infarction.
• B. It dissolves existing clots in blood vessels.
• C. It reduces heart rate.
• D. It increases platelet production.

Answer: (A)

Aspirin is described as an antiplatelet agent because its main effect is to prevent platelets from sticking together and forming clots. It achieves this by irreversibly inhibiting COX-1 in platelets, which stops the production of thromboxane A2, a chemical that promotes platelet aggregation and vasoconstriction. Since platelets cannot synthesize new COX-1, this antiplatelet effect lasts for the platelet’s lifetime, helping to slow or prevent clot growth during a suspected heart attack. It does not dissolve existing clots (that would be a thrombolytic action), and it does not reduce heart rate or increase platelet production. In EMS, prompt aspirin use helps limit clot progression while awaiting further treatment.

Aspirin is described as an antiplatelet agent because its main effect is to prevent platelets from sticking together and forming clots. It achieves this by irreversibly inhibiting COX-1 in platelets, which stops the production of thromboxane A2, a chemical that promotes platelet aggregation and vasoconstriction. Since platelets cannot synthesize new COX-1, this antiplatelet effect lasts for the platelet’s lifetime, helping to slow or prevent clot growth during a suspected heart attack. It does not dissolve existing clots (that would be a thrombolytic action), and it does not reduce heart rate or increase platelet production. In EMS, prompt aspirin use helps limit clot progression while awaiting further treatment.